Core Insights - Immunocore Holdings plc is a biotechnology company focused on developing T cell receptor-based therapeutics, currently in the development stage with high R&D costs before achieving profitability [1] - The company's Return on Invested Capital (ROIC) is -1.74%, and its Weighted Average Cost of Capital (WACC) is 7.98%, indicating it is not generating returns above its cost of capital [2][6] - The ROIC to WACC ratio for Immunocore is -0.22, which is better than some peers, suggesting a relatively better potential for capital efficiency improvement [2][6] Peer Comparison - Vor Biopharma Inc. has a ROIC of -232.79% and a WACC of 9.67%, resulting in a ROIC to WACC ratio of -24.09 [3] - Cullinan Therapeutics, Inc. reports a ROIC of -53.35% and a WACC of 4.55, leading to a ROIC to WACC ratio of -11.72 [3] - Sana Biotechnology, Inc. has a ROIC of -57.87% and a WACC of 12.06, resulting in a ROIC to WACC ratio of -4.80 [3] - Design Therapeutics, Inc. stands out with a ROIC of -38.71% and a WACC of 11.33, achieving the highest ROIC to WACC ratio of -3.42, indicating a closer potential to achieving positive returns [4] Industry Context - All companies analyzed, including Immunocore, are operating with negative ROIC, which is typical for early-stage biotechnology firms [5][6] - Investors should consider ROIC and WACC metrics alongside other factors such as pipeline progress, market potential, and financial health when evaluating investment opportunities in the biotechnology sector [5]

Core Viewpoint - The article discusses the poor performance of actively managed equity funds established in 2021, with over 50% of them still showing negative returns despite the A-share market recovering above 4000 points [1]. Fund Performance Summary - A total of 667 actively managed equity funds established in 2021 were analyzed, revealing that approximately 362 funds have negative returns since inception, accounting for over 50% of the sample [1]. - Among these, 86 funds have experienced declines of over 30%, and 34 funds have seen declines exceeding 40% [1]. - Specific funds such as Qianhai Kaiyuan Public Health Theme Select and others have reported losses greater than 50% since their inception [1]. Specific Fund Data - Qianhai Kaiyuan Public Health Stock A/C, established on March 25, 2021, has a return of -57.80% and -58.60% as of February 5, 2026, with a cumulative loss nearing 60% [2]. - The fund's top ten holdings include companies like Tigermed, WuXi AppTec, and BeiGene [1]. - Qianhai Kaiyuan Public Health Stock A/C has a scale of 0.83 billion yuan as of December 31, 2025 [2]. Additional Fund Performance - Qianhai Kaiyuan Quality Enterprises 6-Month Holding Mixed A/C, established on January 8, 2021, has cumulative returns of -40.78% and -43.14% [3]. - The fund's top holdings include major companies such as Tencent and Alibaba, but its performance has been subpar since 2026 [4].

Group 1: Market Movements - Several biotech and healthcare companies experienced notable gains in after-hours trading, driven by earnings updates, guidance announcements, and broader investor sentiment [1] - FibroBiologics, Inc. (FBLG) led with a 7.68% increase, closing at $0.41, suggesting speculative interest or technical momentum [1] - Nyxoah SA (NYXH) advanced 3.94% to $5.28 after reporting preliminary results for Q4 and full year 2025, along with revenue guidance for Q1 2026 [2] - Fortress Biotech, Inc. (FBIO) climbed 6.90% to $4.49, continuing a trend of volatility despite no new news [2] - Revvity, Inc. (RVTY) gained 4.92% to close at $109.00, with investors likely reacting to a previous collaboration announcement with Eli Lilly [3] - Option Care Health, Inc. (OPCH) rose 3.28% to $33.11 after releasing preliminary unaudited financial results for Q4 and full year 2025, along with guidance for 2026 [4] - Actinium Pharmaceuticals, Inc. (ATNM) added 3.02% to close at $1.34, reflecting investor activity in the broader biotech sector [4] - Design Therapeutics, Inc. (DSGN) gained 1.97% to $9.30, indicating continued interest despite no specific news [5] Group 2: Company-Specific Developments - FibroBiologics, Inc. (FBLG) showed a significant rise without any company-specific news, indicating potential speculative interest [1] - Nyxoah SA (NYXH) provided revenue guidance for Q1 2026, which bolstered investor confidence in its growth trajectory [2] - Revvity, Inc. (RVTY) is expanding access to predictive models through a collaboration with Eli Lilly, aimed at accelerating AI-enabled drug discovery [3] - Option Care Health, Inc. (OPCH) released preliminary financial results and guidance, contributing to its positive after-hours reaction [4]

Core Insights - Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company focused on T cell receptor-based therapeutics for cancer, infectious diseases, and autoimmune conditions [1] - The company operates in a competitive landscape alongside peers such as Vor Biopharma Inc. (VOR), Cullinan Therapeutics, Inc. (CGEM), Sana Biotechnology, Inc. (SANA), and Design Therapeutics, Inc. (DSGN) [1] Financial Performance - Immunocore's Return on Invested Capital (ROIC) is -4.49%, which is below its Weighted Average Cost of Capital (WACC) of 6.55%, resulting in a ROIC to WACC ratio of -0.68 [2][5] - This indicates that Immunocore is not generating returns above its cost of capital, but it shows relatively better capital efficiency compared to its peers [2][5] Peer Comparison - Vor Biopharma Inc. (VOR) has a significantly lower ROIC of -232.79% against a WACC of 9.33%, leading to a ROIC to WACC ratio of -24.95, indicating poorer capital efficiency compared to Immunocore [3] - Cullinan Therapeutics, Inc. (CGEM) and Sana Biotechnology, Inc. (SANA) also exhibit negative ROIC to WACC ratios of -11.508 and -6.208, respectively, suggesting less efficient capital utilization than Immunocore [3] - Design Therapeutics, Inc. (DSGN) has the highest ROIC to WACC ratio among peers at -3.055, but Immunocore maintains a relatively strong position with potential for improvement in capital utilization [4][5]

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones increasing by over 250 points on Thursday [1] Group 2: Notable Company Performances - Nutex Health Inc reported quarterly sales of $267.804 million, surpassing market estimates of $213.812 million, leading to a 37.3% increase in share price to $154.14 [1] - PACS Group, Inc. shares rose by 50.9% to $25.46 following better-than-expected quarterly sales results [3] - Cerence Inc's shares jumped 37.3% to $10.88 after announcing better-than-expected fourth-quarter financial results, with Goldman Sachs maintaining a Neutral rating and raising the price target from $10 to $11 [3] - New Fortress Energy Inc saw a 20.7% increase in share price to $1.40 [3] - Aduro Clean Technologies Inc gained 18.5% to $11.72 after a major global firm completed pilot-scale steam-cracking trials using its technology [3] - Exact Sciences Corp's shares increased by 17.6% to $101.34 after Abbott agreed to acquire the company for $105 per share, valuing the deal at approximately $20 billion [3] - Olema Pharmaceuticals Inc rose 17.3% to $22.78 [3] - Design Therapeutics Inc gained 13.9% to $8.36, with RBC Capital upgrading the stock from Sector Perform to Outperform and raising the price target from $6 to $13 [3] - Terawulf Inc's shares increased by 11.5% to $13.64 [3] - Cipher Mining Inc rose 10.6% to $16.17 after announcing a 10-year deal with Fluidstack for an additional 39 megawatts of critical IT load [3] - IREN Ltd's shares increased by 10.2% to $50.50 [3] - JOYY Inc gained 7.6% to $64.52 after reporting better-than-expected third-quarter financial results and issuing fourth-quarter sales guidance above estimates [3] - Walmart Inc's shares rose 6.5% to $107.17 after reporting third-quarter financial results and raising FY26 revenue and adjusted EPS outlook, along with a transfer of its listing from NYSE to Nasdaq effective Dec. 9 [3] - Guardant Health Inc surged 8.8% to $108.37 [3]

Core Insights - Immunocore Holdings plc (NASDAQ:IMCR) is a biotechnology company focused on T cell receptor-based therapeutics, operating in a capital-intensive industry where efficiency is critical [1] Financial Performance - Immunocore's Return on Invested Capital (ROIC) is -4.49%, while its Weighted Average Cost of Capital (WACC) is 6.65%, indicating that the company is not generating returns above its cost of capital [2][5] - The ROIC to WACC ratio for Immunocore is -0.675, suggesting inefficiency in capital utilization compared to its cost [2] Peer Comparison - Vor Biopharma Inc. (VOR) has a significantly lower ROIC of -232.79% and a WACC of 8.17%, resulting in a ROIC to WACC ratio of -28.49, indicating even poorer capital efficiency than Immunocore [3] - Cullinan Therapeutics, Inc. (CGEM) and Sana Biotechnology, Inc. (SANA) also exhibit negative ROIC to WACC ratios of -11.51 and -6.34, respectively, reflecting similar challenges in generating returns above capital costs [3] - Design Therapeutics, Inc. (DSGN) has the highest ROIC to WACC ratio among peers at -3.01, suggesting relatively better capital utilization despite still being negative [4][5]

Core Insights - Design Therapeutics, Inc. is advancing its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) and will present updates at Eyecelerator @ Park City 2025 on May 2, 2025 [1] - DT-168 is a GeneTAC® small molecule eye drop targeting the CTG repeat expansion in the TCF4 gene to reduce mutant gene expression linked to FECD [2] - The Phase 1 trial results for DT-168 will be showcased, highlighting its potential to restore endothelial function in a disease with no current disease-modifying treatments [3] Company Overview - Design Therapeutics is a clinical-stage biotechnology company focused on developing GeneTAC® therapies aimed at addressing serious degenerative genetic diseases [4] - The company is also developing DT-216P2 for Friedreich ataxia and has programs targeting myotonic dystrophy type-1 and Huntington's disease [4]

CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals. “We are thrilled to we ...